T. Rowe Price Investment Management’s Xenon Pharmaceuticals XENE Stock Holding History

T. Rowe Price Investment Management’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$131M	Buy	2,168,581 +1,216,626	+128%	+$67.5M	0.09%	230
2026 Q1	$55.4M	Buy	951,955 +404,342	+74%	+$18.6M	0.04%	334
2025 Q4	$24.5M	Sell	547,613 -51,500	-9%	-$2.16M	0.02%	463
2025 Q3	$24.1M	Buy	599,113 +522,170	+679%	+$18.4M	0.01%	484
2025 Q2	$2.41M	Sell	76,943 -720,043	-90%	-$23.5M	﹤0.01%	597
2025 Q1	$26.7M	Sell	796,986 -640,845	-45%	-$24.3M	0.02%	482
2024 Q4	$56.4M	Sell	1,437,831 -65,977	-4%	-$2.73M	0.03%	391
2024 Q3	$59.2M	Buy	1,503,808 +63,905	+4%	+$2.58M	0.04%	377
2024 Q2	$56.1M	Buy	1,439,903 +13,564	+1%	+$542K	0.04%	373
2024 Q1	$61.4M	Buy	1,426,339 +535,190	+60%	+$24.6M	0.04%	360
2023 Q4	$41M	Buy	+891,149	New	+$31.5M	0.03%	410

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

T. Rowe Price Investment Management's XENE Position: Q2 2026 in Review

T. Rowe Price Investment Management increased its Xenon Pharmaceuticals (XENE) stake by 128% in Q2 2026, buying an estimated $67.5M and bringing the position to 2,168,581 shares worth $131M. The position accounts for 0.09% of the portfolio, ranked #230.

T. Rowe Price Investment Management first reported a position in XENE in Q4 2023 and has held it in 11 quarters since. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

T. Rowe Price Investment Management held 2,168,581 shares of Xenon Pharmaceuticals worth $131M as of Q2 2026.
T. Rowe Price Investment Management bought 1,216,626 Xenon Pharmaceuticals shares in Q2 2026, an estimated $67.5M.
Xenon Pharmaceuticals made up 0.09% of T. Rowe Price Investment Management's portfolio in Q2 2026, its #230 holding.
T. Rowe Price Investment Management first reported a position in Xenon Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on T. Rowe Price Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.